Revenue climbed 6.6% while adjusted EBITDA hit a 13-quarter high.

Claritev's modeled fair value has been reset from about US$36.83 to roughly US$43.83, which points to a 19% uplift in the updated price target framework. Analysts link this shift to fresh research that balances optimism around bookings, guidance and execution against concerns about leverage, antitrust headlines and the pace of improvement. As you read on, you will see how these moving pieces shape the evolving Claritev story and what that might mean for your own watchlist. Analyst Price...

Moby summary of Claritev Corporation's Q2 2026 earnings call

Claritev (NYSE:CTEV) reported second-quarter revenue growth, record bookings and higher cash flow, prompting the healthcare technology company to raise its full-year revenue, adjusted EBITDA and free-cash-flow outlook. Revenue totaled $257.5 million in the second quarter, up 6.6% from a year earlie

Claritev Corp (CTEV) beats expectations with 6.6% revenue growth and record $74 million ACV bookings in the first half of 2026, driven by claims intelligence and AI initiatives.

Claritev Corporation (NYSE:CTEV) reported second-quarter 2026 results that surpassed Wall Street expectations, driven by solid revenue growth and stronger-than-anticipated earnings. The healthcare technology company also increased its financial guidance for the full year, reflecting confidence in its operating performance.

Claritev Corporation (CTEV) delivered earnings and revenue surprises of +14.88% and +4.60%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (EVH) delivered earnings and revenue surprises of +300.00% and +6.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

UnitedHealth Group stock has delivered a 54.8% return over the past year, yet the broader valuation checks point to a mixed picture rather than a straightforward bargain or clear overvaluation. UnitedHealth Group's 54.8% gain over the last 12 months puts recent buyers in a strong position, but it also raises the bar for what counts as good value from here. On the positive side, recent earnings strength and margin improvements can support the case that the current price still reflects...

The U.S. Department of Justice has expanded an antitrust investigation to include UnitedHealth Group's Claritev unit. The Claritev review is part of broader DOJ scrutiny of healthcare industry practices and market competition. This development adds a fresh layer of regulatory attention for UnitedHealth Group (NYSE:UNH) beyond routine oversight. UnitedHealth Group, one of the largest managed care and healthcare services companies in the U.S., spans insurance, care delivery, and data-driven...

Healthcare stocks fell late Tuesday afternoon with the NYSE Healthcare Index declining 1.7% and the

(Updates with Claritev's response in the fourth paragraph.) The US Justice Department recently se